Cagrilintide
Clinical-stage amylin-pathway weight peptide — not FDA-approved alone.
Ref $ —reference only
CagrilintideIn clinical trials · Not yet FDA-approvedWhat it's for
Clinical-stage amylin-pathway weight peptide — not FDA-approved alone.
What it's for
Cagrilintide is a lab-made peptide related to amylin, a natural hormone that helps fullness and meal spacing.
What it does for the body
It is studied for weight management, sometimes combined with GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicines in research (for example CagriSema programs). People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Amylin-pathway signaling supports feeling full and slowing stomach emptying. Imagine a fullness thermostat separate from, but complementary to, GLP-1 (a gut hormone signal for fullness and blood-sugar handling). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Cagrilintide is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Cagrilintide — FDA.gov search
- ClinicalTrials.gov search: Cagrilintide — U.S. clinical trials registry
- Drugs@FDA search: Cagrilintide — FDA drug database (if approved)
- PubMed search: Cagrilintide — NCBI PubMed
- PubMed Central search: Cagrilintide — NCBI PMC
Reference
No ref on file.